Priscilla Hollander
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1417988098
Payments from drug & device makers
Across 757 payments — averaging $1329.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$926K
- Janssen Research & Development, LLC$25K
- Sanofi US Services Inc.$21K
- Takeda Pharmaceuticals U.S.A., Inc.$17K
- Boehringer Ingelheim$12K
- Novo Nordisk$2K
- plus $3K from 24 others
Across 1 payment — averaging $246.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$246
What the payments were for
- Consulting fees$1,87034%
- Speaking & faculty fees$1,16321%
- Food & beverage$2,50745%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 613 | $926,428 |
| Janssen Research & Development, LLC | 13 | $25,329 |
| Sanofi US Services Inc. | 4 | $20,539 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16,871 |
| Boehringer Ingelheim | 16 | $11,809 |
| Novo Nordisk | 13 | $2,249 |
| Sanofi-aventis U.S. LLC | 7 | $1,232 |
| AstraZeneca | 8 | $224 |
| Amgen | 7 | $219 |
| Johnson & Johnson | 8 | $211 |
| Merck | 4 | $209 |
| Lilly USA, LLC | 12 | $175 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Dexcom, Inc. | 6 | $120 |
| Mannkind Corporation | 7 | $117 |
| Radius Health, Inc. | 6 | $115 |
| AbbVie | 5 | $89 |
| IBSA Pharma Inc. | 5 | $77 |
| Medtronic | 4 | $69 |
| Amarin Pharma, Inc. | 3 | $62 |
| BD | 2 | $48 |
| Ascensia Diabetes Care US Inc. | 2 | $38 |
| Insulet Corporation | 2 | $26 |
| Amneal Pharmaceuticals LLC | 2 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,006,508 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 12 | $269 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Dallas
- Julio RosenstockDallas$24.9M
- Ildiko LingvayDallas$8.2M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
- Michelle WelchShavano Park$17.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.